Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies - PubMed (original) (raw)

Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies

H Hamada et al. Proc Natl Acad Sci U S A. 1986 Oct.

Abstract

An overexpression of the plasma membrane glycoprotein of relative molecular size 170-180 kDa is consistently found in different multidrug-resistant human and animal cell lines, although the functional role of the protein in multidrug resistance is not known. Two monoclonal antibodies that interfere with biochemical functions were generated against the human myelogenous leukemia K-562 cells resistant to adriamycin (K-562/ADM). These antibodies, designated MRK16 and MRK17, are specifically reactive to K-562/ADM and a human ovarian cancer cell line resistant to adriamycin (2780AD). MRK16 modulated vincristine and actinomycin D transport in the resistant cells, while MRK17 specifically inhibited the growth of the resistant cells. Both antibodies recognized the 170- to 180-kDa glycoprotein. These data indicate that the 170- to 180-kDa glycoprotein is involved, directly or indirectly, in the drug transport mechanisms and the proliferation of multidrug-resistant tumor cell lines.

PubMed Disclaimer

Similar articles

• Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells.
  Hamada H, Okochi E, Watanabe M, Oh-hara T, Sugimoto Y, Kawabata H, Tsuruo T. Hamada H, et al. Cancer Res. 1988 Dec 15;48(24 Pt 1):7082-7. Cancer Res. 1988. PMID: 2903793
• [Expression and function of proteins associated with multidrug resistance].
  Hamada H, Tsuruo T. Hamada H, et al. Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):585-91. Gan To Kagaku Ryoho. 1989. PMID: 2565102 Review. Japanese.
• Antibodies in the study of multiple drug resistance.
  Heike Y, Tsuruo T. Heike Y, et al. Cytotechnology. 1993;12(1-3):91-107. doi: 10.1007/BF00744659. Cytotechnology. 1993. PMID: 7764460 Review.

Cited by

• Immunocytochemical identification and localization of the Mr 22,000 calcium-binding protein (sorcin) in an adriamycin-resistant myelogenous leukemia cell line.
  Sugawara I, Mizumoto K, Ohkochi E, Hamada H, Tsuruo T, Mori S. Sugawara I, et al. Jpn J Cancer Res. 1989 May;80(5):469-74. doi: 10.1111/j.1349-7006.1989.tb02338.x. Jpn J Cancer Res. 1989. PMID: 2568983 Free PMC article.
• Mechanisms of multidrug resistance and implications for therapy.
  Tsuruo T. Tsuruo T. Jpn J Cancer Res. 1988 Mar;79(3):285-96. doi: 10.1111/j.1349-7006.1988.tb01588.x. Jpn J Cancer Res. 1988. PMID: 3131279 Free PMC article. Review. No abstract available.
• Multidrug resistance (mdr) genes in human cancer.
  Nooter K, Herweijer H. Nooter K, et al. Br J Cancer. 1991 May;63(5):663-9. doi: 10.1038/bjc.1991.152. Br J Cancer. 1991. PMID: 1674875 Free PMC article. Review. No abstract available.
• Biological response modifiers in the management of patients with breast cancer.
  Longo DL, Hartmann LC. Longo DL, et al. Breast Cancer Res Treat. 1990 Sep;16(2):67-87. doi: 10.1007/BF01809291. Breast Cancer Res Treat. 1990. PMID: 2265261 Review.
• Flow cytometric analysis of P-glycoprotein in normal and leukemic cells.
  Tiirikainen MI, Syrjälä MT, Jansson SE, Krusius T. Tiirikainen MI, et al. Ann Hematol. 1992 Sep;65(3):124-30. doi: 10.1007/BF01695811. Ann Hematol. 1992. PMID: 1356449

References

1. 1. Cancer Res. 1979 Jun;39(6 Pt 1):2070-6 - PubMed
2. 1. Cancer Res. 1978 Dec;38(12):4722-7 - PubMed
3. 1. Cancer Res. 1981 May;41(5):1967-72 - PubMed
4. 1. Methods Enzymol. 1981;73(Pt B):3-46 - PubMed
5. 1. Nature. 1982 Jan 14;295(5845):116-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • Cellosaurus - a cell line knowledge resource